

2019 State Profile — California

National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients (collected every other year) in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2019 N-SSATS report:

<https://www.samhsa.gov/data/data-we-collect/n-ssats-national-survey-substance-abuse-treatment-services>

In California, 1,797 substance abuse treatment facilities were included in the 2019 N-SSATS report, which reported a total of 96,960 clients in substance abuse treatment on March 29, 2019. The survey response rate in California was 84.6 percent.

Facility operation, by number and percent

	Clients in treatment on March 29, 2019					
	Facilities		All clients		Clients under the age of 18 years	
	No.	%	No.	%	No.	%
Private non-profit	808	45.0	38,528	39.7	2,546	70.6
Private for-profit	780	43.4	47,075	48.6	322	8.9
Local, county, or community government	149	8.3	8,028	8.3	732	20.3
State government	4	0.2	125	0.1	—	—
Federal government	35	1.9	2,882	3.0	4	0.1
Tribal government	21	1.2	322	0.3	2	0.1
Total	1,797	100.0	96,960	100.0	3,606	100.0

Note: Percentages may not sum to 100 percent due to rounding.

Substance abuse problem treated, by number and percent

	Clients in treatment on March 29, 2019				
	Facilities ¹		Clients ²		Clients ² per 100,000 pop. aged 18 years or older
	No.	%	No.	%	
Clients with both alcohol and drug abuse	1,143	88.5	29,091	29.0	89
Clients with drug abuse only	1,069	82.7	60,312	60.1	193
Clients with alcohol abuse only	951	73.6	10,894	10.9	34
Total			100,298	100.0	316

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Facility capacity and utilization rate¹

	Residential	Hospital inpatient
Number of facilities	531	30
Number of clients ²	11,536	592
Number of designated beds	12,955	638
Utilization rate ³	89.0	92.8
Average number of designated beds per facility	24	21

¹ Excludes facilities not reporting both client counts and number of beds, facilities whose client counts were reported by another facility, facilities that included client counts from other facilities, and facilities that did not respond to this question.

² Number of clients on March 29, 2019.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

For a symbol key, see the last page of this profile.

Type of care, by number and percent

	Clients in treatment on March 29, 2019							
	Facilities		All clients				Clients under the age of 18 years	
	No.	%	No.	%	Median no. of	Median no. of	No.	%
					clients per	clients per		
				OTP facility	non-OTP facility			
Outpatient	1,085	60.4	83,534	86.2	295	29	3,372	93.5
Regular	979	54.5	30,915	31.9	102	20		
Intensive	688	38.3	8,719	9.0	27	10		
Day treatment or partial hospitalization	324	18.0	1,912	2.0	40	7		
Detoxification	236	13.1	976	1.0	4	5		
Methadone/buprenorphine maintenance or naltrexone treatment	360	20.0	41,012	42.3	255	6		
Residential (non-hospital)	823	45.8	12,752	13.2	132	12	222	6.2
Short term (≤ 30 days)	644	35.8	3,715	3.8	87	6		
Long term (> 30 days)	704	39.2	7,573	7.8	45	12		
Detoxification	484	26.9	1,464	1.5	—	3		
Hospital inpatient	70	3.9	674	0.7	32	12	12	0.3
Treatment	49	2.7	345	0.4	1	6		
Detoxification	64	3.6	329	0.3	63	6		
Total	1,797		96,960	100.0	300	20	3,606	100.0

Note: Facilities may provide more than one type of care.

Facility licensing, certification, or accreditation, by number and percent

	No.	%
Any listed agency/organization	1,706	94.9
State substance abuse agency	1,301	72.4
State mental health department	248	13.8
State department of health	959	53.4
Hospital licensing authority	51	2.8
The Joint Commission	526	29.3
Commission on Accreditation of Rehabilitation Facilities (CARF)	426	23.7
National Committee for Quality Assurance (NCQA)	45	2.5
Council on Accreditation (COA)	61	3.4
Healthcare Facilities Accreditation Program (HFAP)	11	0.6
Other national organization or federal, state, or local agency	70	3.9

Note: Facilities may be licensed, certified, or accredited by more than one agency/organization.

Facility payment options, by number and percent

	No.	%
Cash or self-payment	1,511	84.1
Private health insurance	1,130	62.9
Medicare	362	20.1
Medicaid	685	38.1
State-financed health insurance plan other than Medicaid	432	24.0
Federal military insurance	391	21.8
No payment accepted (free treatment for all clients)	73	4.1
IHS/Tribal/Urban (ITU) funds	291	16.2
Other	14	0.8
Sliding fee scale	961	53.5
Treatment at no charge or minimal payment for clients who can't pay	742	41.3

Note: Facilities may accept more than one type of payment.

Types of services offered, by number and percent

	Facilities	
	No.	%
Assessment and pre-treatment services		
Screening for substance abuse	1,729	96.2
Screening for mental health disorders	1,273	70.8
Comprehensive substance abuse assessment or diagnosis	1,633	90.9
Comprehensive mental health assessment or diagnosis	809	45.0
Screening for tobacco use	1,123	62.5
Outreach to persons in the community who may need treatment	1,225	68.2
Interim services for clients when immediate admission is not possible	786	43.7
Professional interventionist/educational consultant	357	19.9
None of these assessment and pre-treatment services offered	50	2.8
Testing		
Drug and alcohol oral fluid testing	504	28.0
Breathalyzer or other blood alcohol testing	1,325	73.7
Drug or alcohol urine screening	1,625	90.4
Testing for hepatitis B	403	22.4
Testing for hepatitis C	475	26.4
HIV testing	550	30.6
STD testing	460	25.6
TB screening	818	45.5
Testing for metabolic syndrome	117	6.5
None of these testing services offered	117	6.5
Medical services		
Hepatitis A (HAV) vaccination	136	7.6
Hepatitis B (HBV) vaccination	136	7.6
None of these medical services offered	1,651	91.9
Transitional services		
Discharge planning	1,717	95.5
Aftercare/continuing care	1,500	83.5
Naloxone and overdose education	838	46.6
Outcome follow-up after discharge	1,420	79.0
None of these transitional services offered	36	2.0
Recovery support services		
Mentoring/peer support	1,301	72.4
Self-help groups (for example, AA, NA, SMART Recovery)	1,198	66.7
Assistance in locating housing for clients	1,306	72.7
Employment counseling or training for clients	932	51.9
Assistance with obtaining social services (for example, Medicaid, WIC, SSI, SSDI)	1,287	71.6
Recovery coach	335	18.6
None of these recovery support services offered	99	5.5
Education and counseling services		
HIV or AIDS education, counseling, or support	1,104	61.4
Hepatitis education, counseling, or support	1,015	56.5
Health education other than HIV/AIDS or hepatitis	1,080	60.1
Substance abuse education	1,759	97.9
Smoking/ tobacco cessation counseling	902	50.2
Individual counseling	1,760	97.9

Continued

For a symbol key, see the last page of this profile.

Types of services offered, by number and percent (continued)

	Facilities	
	No.	%
Group counseling	1,698	94.5
Family counseling	1,373	76.4
Marital/couples counseling	941	52.4
Vocational training or educational support	394	21.9
None of these education and counseling services offered	13	0.7
Pharmacotherapies		
Disulfiram (Antabuse®)	474	26.4
Naltrexone (oral)	645	35.9
Naltrexone (extended-release, injectable, for example, Vivitrol®)	579	32.2
Acamprosate (Campral®)	409	22.8
Nicotine replacement	546	30.4
Non-nicotine smoking/tobacco cessation medications (for example, bupropion, varenicline)	439	24.4
Medications for psychiatric disorders	737	41.0
Methadone ¹	144	8.0
Buprenorphine with naloxone (for example, Suboxone®, Bunavail®, Zubsolv®, Cassipa®)	719	40.0
Buprenorphine without naloxone	527	29.3
Buprenorphine sub-dermal implant (Probuphine®)	113	6.3
Buprenorphine (extended-release, injectable, for example, Sublocade®)	239	13.3
Medications for HIV treatment (for example, antiretroviral medications such as tenofovir, efavirenz, emtricitabine, atazanavir, and lamivudine)	215	12.0
Medications for hepatitis C (HCV) treatment (for example, sofosbuvir, ledipasvir, interferon, peginterferon, ribavirin)	224	12.5
Lofexidine	108	6.0
Clonidine	492	27.4
None of these pharmacotherapy services offered	795	44.2
Ancillary services		
Case management services	1,652	91.9
Social skills development	1,502	83.6
Child care for clients' children	186	10.4
Domestic violence—family or partner violence services (physical, sexual, and emotional abuse)	686	38.2
Early intervention for HIV	490	27.3
Transportation assistance to treatment	983	54.7
Mental health services	1,117	62.2
Acupuncture	187	10.4
Residential beds for clients' children	90	5.0
None of these ancillary services offered	38	2.1
Other services		
Treatment for gambling disorder	292	16.2
Treatment for Internet use disorder	241	13.4
Treatment for other addiction disorder (non-substance abuse)	506	28.2
None of these 'other' services offered	1,257	69.9

¹ Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment.

Clinical/therapeutic approaches used frequently, by number and percent

	Facilities	
	No.	%
Substance abuse counseling	1,775	98.8
12-step facilitation	1,330	74.0
Brief intervention	1,451	80.7
Cognitive behavioral therapy	1,676	93.3
Dialectical behavior therapy	1,100	61.2
Contingency management/motivational incentives	1,113	61.9
Motivational interviewing	1,697	94.4
Trauma-related counseling	1,523	84.8
Anger management	1,499	83.4
Matrix model	914	50.9
Community reinforcement plus vouchers	245	13.6
Rational emotive behavioral therapy (REBT)	642	35.7
Relapse prevention	1,756	97.7
Telemedicine/telehealth	456	25.4
Other treatment approaches	230	12.8
We do not use any of these clinical/therapeutic approaches	2	0.1

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	1,542	85.8
Adolescents	312	17.4
Young adults	673	37.5
Adult women	999	55.6
Pregnant or postpartum women	480	26.7
Adult men	981	54.6
Seniors or older adults	533	29.7
LGBT clients	575	32.0
Veterans	502	27.9
Active duty military	263	14.6
Members of military families	340	18.9
Criminal justice clients (other than DUI/DWI)	686	38.2
Clients with co-occurring mental and substance use disorders	1,052	58.5
Clients with co-occurring pain and substance use	447	24.9
Clients with HIV or AIDS	491	27.3
Clients who have experienced sexual abuse	657	36.6
Clients who have experienced intimate partner violence, domestic violence	631	35.1
Clients who have experienced trauma	951	52.9
DUI/DWI clients	124	6.9
Other	102	5.7
No specifically tailored programs or groups are offered	255	14.2

DUI/DWI = driving under the influence/driving while intoxicated or impaired; LGBT = lesbian, gay, bisexual, or transgender.

Facility funding, by number and percent

	Facilities	
	No.	%
Receives federal, state, county, or local government funds or grants for substance use treatment programs	796	44.3

Services in sign language for the deaf and hard-of-hearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	422	23.5
Any language other than English	919	51.1

Non-English language provided by

Staff counselor only	342	37.2
On-call interpreter only	151	16.4
Both staff counselor and on-call interpreter	426	46.4

Languages provided by staff counselor¹

Spanish	740	96.4
American Indian/Alaska Native languages	8	1.0
Other	155	20.2

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Symbol key (where applicable)

— Quantity is zero; * Less than 0.05 percent;
 † Less than 1 per 100,000; ‡ No facilities in this category.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 29, 2019. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: <https://www.samhsa.gov/data/data-we-collect/n-ssats-national-survey-substance-abuse-treatment-services>

Access the latest N-SSATS public use files at: <https://datafiles.samhsa.gov>

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at: <https://findtreatment.samhsa.gov/>



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
 Substance Abuse and Mental Health Services Administration
 Center for Behavioral Health Statistics and Quality
www.samhsa.gov/data

Clients receiving medication-assisted opioid therapy (MAOT) at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by number and percent

	No.	%
Facilities with OTPs¹	144	8.5

Clients in facilities with OTPs²

Any MAT ³	39,916	8.9
Methadone	38,892	9.5
Buprenorphine	942	2.6
Naltrexone	82	2.7

Clients in facilities without OTPs⁴

Any MAT ⁵	9,110	5.7
Buprenorphine	8,201	6.2
Naltrexone	909	3.3

¹ Percentage of all facilities with OTPs in the U.S. ² Percentage of all clients receiving methadone, buprenorphine, or naltrexone at facilities with OTPs in the U.S.; see 2019 N-SSATS report for details. ³ Consists of clients receiving methadone, buprenorphine, or naltrexone. ⁴ Percentage of all clients receiving buprenorphine or naltrexone at non-OTP facilities in the U.S.; see 2019 N-SSATS report for details. ⁵ Consists of clients receiving buprenorphine or naltrexone.

Clients per 100,000 population receiving MAOT in OTP facilities on March 29, 2019

	No.
Any type of medication-assisted therapy ¹	101
Methadone	98
Buprenorphine	2
Naltrexone	†

¹ Includes clients receiving methadone, buprenorphine, or naltrexone.

Location of treatment facilities



<https://www.samhsa.gov/data/quick-statistics>